Dr. Christophe Arbet-Engels talks about how empagliflozin differs from other SGLT-2 inhibitors already on the market such as canagliflozin and dapagliflozin, stating that empagliflozin is “very specific” to its target, but hasn’t yet been compared to the others so it is too early to tell what other differences there might be. …

  Robert E. Ratner, MD, talks about the best way to screen for prediabetes, and the importance of balancing convenience and specificity.  

Robert E. Ratner, MD, talks about how the ADA is working to identify prediabetes and delay the onset as much as possible of diabetes. He explains that screening is extremely important and that this process also provides an opportunity for intervention. He also emphasizes that lifestyle modification is the first step …

  In this week’s Homerun Slides, a closer look at the workings and efficacy of DPP-4 inhibitors…   To download the complete set in PowerPoint format, just use this link: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 8 Catch up on past …

In this week's Homerun Slides, incretins, an explanation of the glucose-stimulated secretion of insulin and the effect of exenatide versus glargine insulin on insulin secretion in type 2 diabetes...

Dr. Christophe Arbet-Engels explains how Eli Lilly and Boehringer Ingelheim have created and alliance and what that means in terms of promotion.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

David Levy, MD, FRCP Diuretics Thiazide diuretics have been the mainstay of antihypertensive treatment since the first potent thiazide was introduced in 1957, and have often been the agents against which other drug classes have been compared in important clinical trials [18]. They are especially useful in low-renin (salt-sensitive) states, for example older people, and black or obese patients. Resistant hypertension (see below), common in these groups, is frequently due to inadequate diuretic therapy. Despite half a century of use, disagreement continues about their optimum dosing and whether blood pressure lowering effects and cardiovascular benefits are common to all agents in the class. There is continuing controversy about their potential metabolic disadvantages – concern about these, together with their low pharmaceutical profile, prevents their being used in many patients – but there is no evidence that these in any way blunt their cardiovascular benefits, even in people with diabetes (Box 11.7). They are as effective in reducing coronary events as any other class of antihypertensive agents, but in ALLHAT were more effective in reducing heart failure and stroke than lisinopril or amlodipine...

The American Diabetes Association ‘Sounds the Alert’ for More Than Six Million Americans

Our Doctor of Pharmacy Candidate from LECOM College of Pharmacy, Diana Jules, has reviewed a new book from the ADA and found that it is a good read for you. See what she has to say.

The diabetes newsletters and services have all been carrying articles about the artificial pancreas. There are three basic components to the device. There is a pump to deliver insulin and a pump to deliver glucagon, however, the “brains” of the system is the glucose reading device. Without the brains, then …